Logo image of ARVN

ARVINAS INC (ARVN) Stock Fundamental Analysis

NASDAQ:ARVN - Nasdaq - US04335A1051 - Common Stock - Currency: USD

17.77  -0.6 (-3.27%)

Premarket: 18.04 +0.27 (+1.52%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ARVN. ARVN was compared to 193 industry peers in the Pharmaceuticals industry. ARVN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARVN is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ARVN has reported negative net income.
In the past year ARVN has reported a negative cash flow from operations.
ARVN had negative earnings in each of the past 5 years.
ARVN had negative operating cash flow in 4 of the past 5 years.
ARVN Yearly Net Income VS EBIT VS OCF VS FCFARVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

1.2 Ratios

With a decent Return On Assets value of -18.22%, ARVN is doing good in the industry, outperforming 64.13% of the companies in the same industry.
ARVN has a better Return On Equity (-35.41%) than 62.50% of its industry peers.
Industry RankSector Rank
ROA -18.22%
ROE -35.41%
ROIC N/A
ROA(3y)-22.88%
ROA(5y)-19.47%
ROE(3y)-47.02%
ROE(5y)-36.82%
ROIC(3y)N/A
ROIC(5y)N/A
ARVN Yearly ROA, ROE, ROICARVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K

1.3 Margins

ARVN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARVN Yearly Profit, Operating, Gross MarginsARVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

ARVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARVN has been increased compared to 1 year ago.
Compared to 5 years ago, ARVN has more shares outstanding
ARVN has a better debt/assets ratio than last year.
ARVN Yearly Shares OutstandingARVN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ARVN Yearly Total Debt VS Total AssetsARVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -0.18, we must say that ARVN is in the distress zone and has some risk of bankruptcy.
ARVN has a Altman-Z score (-0.18) which is in line with its industry peers.
ARVN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ARVN (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.18
ROIC/WACCN/A
WACC9.8%
ARVN Yearly LT Debt VS Equity VS FCFARVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

ARVN has a Current Ratio of 4.64. This indicates that ARVN is financially healthy and has no problem in meeting its short term obligations.
ARVN has a Current ratio of 4.64. This is in the better half of the industry: ARVN outperforms 63.04% of its industry peers.
A Quick Ratio of 4.64 indicates that ARVN has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.64, ARVN is doing good in the industry, outperforming 64.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.64
Quick Ratio 4.64
ARVN Yearly Current Assets VS Current LiabilitesARVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

ARVN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.38%, which is quite impressive.
Looking at the last year, ARVN shows a very strong growth in Revenue. The Revenue has grown by 31.63%.
ARVN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 43.69% yearly.
EPS 1Y (TTM)57.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.1%
Revenue 1Y (TTM)31.63%
Revenue growth 3Y78.01%
Revenue growth 5Y43.69%
Sales Q2Q%237.35%

3.2 Future

The Earnings Per Share is expected to grow by 21.65% on average over the next years. This is a very strong growth
Based on estimates for the next years, ARVN will show a very strong growth in Revenue. The Revenue will grow by 27.68% on average per year.
EPS Next Y-39.85%
EPS Next 2Y-25.14%
EPS Next 3Y-14.67%
EPS Next 5Y21.65%
Revenue Next Year-18.93%
Revenue Next 2Y-6.92%
Revenue Next 3Y7.71%
Revenue Next 5Y27.68%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARVN Yearly Revenue VS EstimatesARVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ARVN Yearly EPS VS EstimatesARVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ARVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARVN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARVN Price Earnings VS Forward Price EarningsARVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARVN Per share dataARVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as ARVN's earnings are expected to decrease with -14.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.14%
EPS Next 3Y-14.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARVN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARVINAS INC

NASDAQ:ARVN (2/21/2025, 8:01:48 PM)

Premarket: 18.04 +0.27 (+1.52%)

17.77

-0.6 (-3.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2025-02-11/bmo
Earnings (Next)05-01 2025-05-01/bmo
Inst Owners108.55%
Inst Owner Change-96.36%
Ins Owners1.92%
Ins Owner Change4.17%
Market Cap1.22B
Analysts85.71
Price Target59.27 (233.54%)
Short Float %16.7%
Short Ratio10.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.11%
Min EPS beat(2)30.66%
Max EPS beat(2)39.55%
EPS beat(4)4
Avg EPS beat(4)36.87%
Min EPS beat(4)30.66%
Max EPS beat(4)44.34%
EPS beat(8)6
Avg EPS beat(8)13%
EPS beat(12)6
Avg EPS beat(12)0.61%
EPS beat(16)6
Avg EPS beat(16)-10.97%
Revenue beat(2)1
Avg Revenue beat(2)31.87%
Min Revenue beat(2)-11.09%
Max Revenue beat(2)74.84%
Revenue beat(4)2
Avg Revenue beat(4)17.54%
Min Revenue beat(4)-29.28%
Max Revenue beat(4)74.84%
Revenue beat(8)4
Avg Revenue beat(8)-4.27%
Revenue beat(12)7
Avg Revenue beat(12)4.38%
Revenue beat(16)10
Avg Revenue beat(16)6.88%
PT rev (1m)-4.42%
PT rev (3m)-8.34%
EPS NQ rev (1m)21.21%
EPS NQ rev (3m)14.84%
EPS NY rev (1m)17.99%
EPS NY rev (3m)18.49%
Revenue NQ rev (1m)9.31%
Revenue NQ rev (3m)18.03%
Revenue NY rev (1m)-1.48%
Revenue NY rev (3m)2.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.64
P/FCF N/A
P/OCF N/A
P/B 2.18
P/tB 2.18
EV/EBITDA N/A
EPS(TTM)-2.77
EYN/A
EPS(NY)-3.87
Fwd EYN/A
FCF(TTM)-3.8
FCFYN/A
OCF(TTM)-3.77
OCFYN/A
SpS3.83
BVpS8.17
TBVpS8.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.22%
ROE -35.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.88%
ROA(5y)-19.47%
ROE(3y)-47.02%
ROE(5y)-36.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.13%
Cap/Sales 0.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.64
Quick Ratio 4.64
Altman-Z -0.18
F-Score4
WACC9.8%
ROIC/WACCN/A
Cap/Depr(3y)69.16%
Cap/Depr(5y)101.08%
Cap/Sales(3y)3.18%
Cap/Sales(5y)9.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.1%
EPS Next Y-39.85%
EPS Next 2Y-25.14%
EPS Next 3Y-14.67%
EPS Next 5Y21.65%
Revenue 1Y (TTM)31.63%
Revenue growth 3Y78.01%
Revenue growth 5Y43.69%
Sales Q2Q%237.35%
Revenue Next Year-18.93%
Revenue Next 2Y-6.92%
Revenue Next 3Y7.71%
Revenue Next 5Y27.68%
EBIT growth 1Y60.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.73%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.45%
OCF growth 3YN/A
OCF growth 5YN/A